Message Pharmaceuticals Inc is categorized under Commercial Medical Research in Malvern, PA and active since 2002.
Message Pharmaceuticals Inc was established in 2002, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Christopher M Cashman at the company’s single location by writing to 30 Spring Mill Drive, Malvern, Pennsylvania PA 19355 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Message Pharmaceuticals Inc |
| Contact Person: | Christopher M Cashman |
| Address: | 30 Spring Mill Drive, Malvern, Pennsylvania 19355 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2002 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Message Pharmaceuticals Inc was started in 2002 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Christopher M Cashman for inquiries that concern Message Pharmaceuticals Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Message Pharmaceuticals Inc can be found at the coordinates 40.070091,-75.554131 as well as the street address 30 Spring Mill Drive in Malvern, Pennsylvania 19355.
For its online presence, you may visit Message Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.